Advancing First-in-Class Small Molecule Inhibitors for Targeting the Intracellular RAGE-Diaph1 Interface with Superior Efficacy
DiaphOne develops first in class small molecule inhibitors targeting the intracellular RAGE-Diaph1 interface. The drug candidates have a profile of increased efficacy, decreased redundancy compared to extracellular ligand blocking and have undergone extensive target validation studies.